Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Appl Immunohistochem Mol Morphol ; 30(2): 91-98, 2022 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-34799503

RESUMEN

The International Endocervical adenocarcinoma Criteria and Classification (IECC) categorizes tumors into human papilloma virus (HPV) associated (HPVA), not associated (NHPV), and invasive adenocarcinoma not otherwise specified (IA NOS). HPVA and NHPV encompass 11 histotypes and an algorithm of mucin content, HPV ribonucleic acid (RNA), estrogen receptor and GATA3 is proposed for the diagnosis of most. In this study, the IECC algorithm's diagnoses were compared with hematoxylin and eosin (H&E) based IECC histotyping. Kappa statistics measured performance agreement. With additional markers, hierarchical clustering by random forest (RF) classification identified the most discriminating between tumor types, and investigated other algorithms. Three pathologists independently reviewed digitized H&E images of n=152 primary cervical adenocarcinomas for IECC histotype and mucin content, and tissue microarrays for expression of HPV RNA by in situ hybridization and 16 antibodies by immunohistochemistry. Results were finalized by consensus. There were n=113 HPVA, n=22 NHPV, and n=17 IA NOS. Mucin was obvious in n=36 and limited in n=116. Among n=124 with satisfactory test results, HPV RNA was positive in n=96, estrogen receptor in n=72, and GATA3 in n=15. The IECC algorithm diagnosed n=99 which agreed with H&E histotyping in n=64 for a fair κ of 0.36 (95% confidence interval, 0.21-0.50): n=12 were undiagnosed and n=13 were IA NOS. Small sample sizes restricted RF to HPVA versus NHPV which were discriminated by p16, HPV RNA, and MUC6 with an area under the curve of 0.74 (95% confidence interval, 0.58-0.90). The IECC algorithm for histotyping under-performed. The RF algorithmin for categorization was favorable, but validation in larger studies and investigation of additional algorithms to discriminate between all IECC histotypes are needed.


Asunto(s)
Adenocarcinoma , Alphapapillomavirus , Carcinoma , Infecciones por Papillomavirus , Neoplasias del Cuello Uterino , Adenocarcinoma/diagnóstico , Adenocarcinoma/patología , Algoritmos , Alphapapillomavirus/genética , Biomarcadores de Tumor , Cuello del Útero/patología , Femenino , Humanos , Mucinas , Papillomaviridae/genética , Infecciones por Papillomavirus/diagnóstico , ARN , Receptores de Estrógenos , Neoplasias del Cuello Uterino/patología
2.
Appl Immunohistochem Mol Morphol ; 29(3): 209-217, 2021 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-33264105

RESUMEN

Immunohistochemistry (IHC) improves the diagnosis of cervical adenocarcinoma but is not adequately studied. The performance of 16 antibodies previously reported as potentially discriminating between some histotypes was investigated in 184 tumors comprised of 12 histotype groups collapsed into 3 categories [47 adenocarcinomas in situ (AIS), 121 probable human papillomavirus-dependent adenocarcinomas (HPVD), and 16 of probable independence (HPVI)]. IHC sections from 5 tissue microarrays were scanned, and 3 pathologists independently reviewed images to assess staining percentages and intensities. Biomarker expression was based on published positive and negative cutoffs and agreement between any 2 pathologists. Differences between the 3 categories in the hierarchical ranking of biomarker positivity were analyzed by Random Forest classification, and between select groups by Unsupervised Hierarchical Clustering. Important category discriminants were combined in logistic regression models and the area under the curve (AUC) computed. Potential group discriminants were terminal cluster biomarkers with a 50% or more difference in positivity. Strong associations occurred between the lower expression of carcinoembryonic antigen and stromal actin in AIS compared with HPVD [AUC=0.70, 95% confidence interval (CI), 0.59-0.80] and in the higher expression of p16 and estrogen receptor in comparison to HPVI (AUC=0.86, 95% CI, 0.73-0.98), and between the higher expression of p16, carcinoembryonic antigen and estrogen receptor in HPVD compared with HPVI (AUC=0.88, 95% CI, 0.77-0.99). Between select groups, 9 biomarkers emerged as potential discriminants. Select IHC biomarkers can discriminate AIS from invasive adenocarcinomas, and invasive adenocarcinomas stratified by human papillomavirus dependency from each other. Independent replication in larger studies is needed, and to confirm discriminants of histotype groups.


Asunto(s)
Adenocarcinoma/metabolismo , Alphapapillomavirus/fisiología , Antígeno Carcinoembrionario/metabolismo , Inhibidor p16 de la Quinasa Dependiente de Ciclina/metabolismo , Infecciones por Papillomavirus/metabolismo , Receptores de Estrógenos/metabolismo , Neoplasias del Cuello Uterino/metabolismo , Adenocarcinoma/diagnóstico , Biomarcadores de Tumor/metabolismo , Análisis por Conglomerados , Femenino , Humanos , Inmunohistoquímica , Infecciones por Papillomavirus/diagnóstico , Neoplasias del Cuello Uterino/diagnóstico
3.
J Obstet Gynaecol Can ; 41(9): 1318-1324, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31006541

RESUMEN

OBJECTIVE: This study aimed to identify clinical and pathological determinants of invasive adenocarcinoma of the uterine cervix (AC) in a large, single-centre series serving a population of 1.5 million. METHODS: Data on clinical (n = 27) and pathological (n = 23) variables for 166 women with a diagnosis of AC treated between 2000 and 2013 were extracted from their charts and pathology reports. Overall survival (OS) was calculated, and significant determinants were identified using Kaplan-Meier analyses and log-rank tests, respectively (Canadian Task Force Classification II-2). RESULTS: This was a heterogeneous group of women with all stages of disease treated with conization, surgery, radiation, and systemic chemotherapy, alone or in combination. Mean age at diagnosis was 43; 86.7% had stage I disease, 9.6% had stage II, and only 3.6% had stage III and IV disease. Mean follow-up was 108 months. Many histotypes were diagnosed and grouped as mucinous (n = 103), endometrioid (n = 15), rare (n = 9), and adenosquamous (n = 39) types. Twenty-eight women had recurrent cancer and died of the disease; OS at 5 years was 85%. Five-year OS for women with stage I was 92%, compared with 40% for stage II or higher. Univariate analysis revealed that premenopausal status, tumour size, first-line treatment with chemotherapy, lymphovascular invasion, rare histological subtypes, stage, and receipt of second-line treatment were all significantly associated with a lower OS. Using multivariate analysis, only stage remained an independent factor. CONCLUSION: This is the largest single-centre Canadian series of invasive AC. Stage is the strongest prognostic factor in multivariate analysis; in contrast to other studies, lymph node status was not a significant determinant.


Asunto(s)
Adenocarcinoma , Estadificación de Neoplasias/estadística & datos numéricos , Neoplasias del Cuello Uterino , Adenocarcinoma/diagnóstico , Adenocarcinoma/epidemiología , Adenocarcinoma/mortalidad , Adulto , Femenino , Humanos , Persona de Mediana Edad , Estudios Retrospectivos , Neoplasias del Cuello Uterino/diagnóstico , Neoplasias del Cuello Uterino/epidemiología , Neoplasias del Cuello Uterino/mortalidad
4.
J Low Genit Tract Dis ; 22(2): 132-138, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29474242

RESUMEN

OBJECTIVE: The aim of the study was to compare the reproducibility of malignant glandular tumors of the uterine cervix classified per World Health Organization (WHO) 2003 and 2014. MATERIALS AND METHODS: Two pathologists reviewed 228 cases composed of adenocarcinoma in situ and 22 adenocarcinoma histotypes and selected 405 representative hematoxylin and eosin slides, which were digitally scanned. Six other pathologists (3 gynecological and 3 anatomical) independently reviewed and classified the images per both WHO classifications. One year later, they classified a random sample of 25 cases. Inter- (inter-OR) and intra-observer (intra-OR) reproducibility of the 6 pathologists and separately for gynecological compared with anatomical pathologists was tested using κ statistics. RESULTS: Both classifications were collapsed into 6 categories as benign, adenocarcinoma in situ, and mucinous, endometrioid, rare, and adenosquamous-miscellaneous carcinomas. WHO 2014 had an additional category: endocervical adenocarcinoma, usual type. Inter-observer κ values were more reliable than the intra-OR results based on 95% CIs. The average inter-OR κ values with both classifications were moderate between the 6 pathologists and between the 3 anatomical pathologists. In contrast, they were substantial between the 3 gynecological pathologists. With both classifications, the average intra-OR κ values of the 6 pathologists and both pathologist groups trended toward substantial. CONCLUSIONS: Reproducibility among 6 pathologists is unaffected by changes in the WHO 2014 classification and averages moderate between different and trends toward substantial between the same pathologist. Reproducibility between different pathologists can improve to substantial when they have expertise in gynecological pathology.


Asunto(s)
Adenocarcinoma/patología , Neoplasias del Cuello Uterino/patología , Adenocarcinoma/clasificación , Adenocarcinoma in Situ , Alberta , Instituciones Oncológicas , Femenino , Humanos , Variaciones Dependientes del Observador , Reproducibilidad de los Resultados , Neoplasias del Cuello Uterino/clasificación , Organización Mundial de la Salud
5.
Appl Immunohistochem Mol Morphol ; 26(2): 140-146, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-27258560

RESUMEN

BACKGROUND: Intestinal-type adenocarcinoma (ITAC) of the nasal cavity and paranasal sinuses is an uncommon tumor associated with exposure to wood and leather dust, nickel, and possibly smoking. ITAC shares phenotypical features with colorectal carcinoma. In contrast to most non-intestinal-type sinonasal adenocarcinomas, ITAC is an aggressive adenocarcinoma with poor clinical outcome; therefore, its reliable separation from non-ITAC is very important. AIM: The use of a combination of immunohistochemical markers of intestinal differentiation was tested in a cohort of sinonasal carcinomas of different types. The aim of this study was to explore a new intestinal marker, SATB2, in conjunction with CDX2 and CK20 in differential diagnosis of sinonasal adenocarcinomas. MATERIALS AND METHODS: Seven ITACs, 66 non-ITACs, and 1 case of extensive intestinal metaplasia (IM) of the nasal mucosa were included in the study and stained with SATB2, CK20, CDX2, and CK7 antibodies. Detection of mismatch repair proteins was performed in all cases of ITAC. All 7 sinonasal ITACs have been tested for KRAS, NRAS, and BRAF gene mutations. RESULTS: All ITACs showed positive expression for SATB2, whereas all non-ITAC cases were negative. The only 1 case of IM was found to be positive for SATB2, whereas the same case showed negative expression of CK20 and only focal immunostaining for CDX2. The genetic analysis showed that only 1 sinonasal ITAC (1/7) showed KRAS c.35G>C, p.(Gly12Ala) mutation, whereas BRAF and NRAS genes were wild type. Four ITACs revealed wild-type KRAS, NRAS, and BRAF, and 2 remaining cases were not analyzable. All ITACs showed preserved nuclear expression of mismatch repair proteins. CONCLUSIONS: SATB2 in combination with CDX2 and CK20 differentiates sinonasal ITAC from non-ITAC with increased diagnostic sensitivity and specificity and detects IM in the sinonasal tract more easily.


Asunto(s)
Adenocarcinoma/metabolismo , Biomarcadores de Tumor/metabolismo , Neoplasias del Colon/metabolismo , Neoplasias Colorrectales/metabolismo , Intestinos/patología , Proteínas de Unión a la Región de Fijación a la Matriz/metabolismo , Neoplasias Nasales/metabolismo , Factores de Transcripción/metabolismo , Adenocarcinoma/diagnóstico , Adenocarcinoma/patología , Anciano , Factor de Transcripción CDX2/metabolismo , Neoplasias del Colon/diagnóstico , Neoplasias del Colon/patología , Neoplasias Colorrectales/diagnóstico , Neoplasias Colorrectales/patología , Diagnóstico Diferencial , Exposición a Riesgos Ambientales/efectos adversos , Femenino , Humanos , Inmunohistoquímica , Queratina-20/metabolismo , Masculino , Metaplasia , Persona de Mediana Edad , Cavidad Nasal/patología , Neoplasias Nasales/diagnóstico , Neoplasias Nasales/patología , Senos Paranasales/patología , Pronóstico , Madera
6.
Hum Pathol ; 42(12): 2018-24, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21733554

RESUMEN

A classification schema for grading Polyomavirus nephropathy was proposed at the 2009 Banff allograft meeting. The schema included 3 stages of Polyomavirus nephropathy: early (stage A), florid (stage B), and late sclerosing (stage C). Grading categories for histologic viral load levels were also proposed. To examine the applicability and the interobserver agreement of the proposed Polyomavirus nephropathy grading schema, we evaluated 24 renal allograft biopsies with confirmed Polyomavirus nephropathy by histology and SV40. Four renal pathologists independently scored the Polyomavirus nephropathy stage (A, B, or C), without knowledge of the clinical history. Viral load was scored as a percent of tubules exhibiting viral replication, using either a 3-tier viral load score (1: ≤1%; 2: >1%-10%; 3: >10%) or a 4-tier score (1: ≤1%; 2: >1%-≤5%; 3: >5%-15%; 4: >15%). The κ score for the Polyomavirus nephropathy stage was 0.47 (95% confidence interval, 0.35-0.60; P < .001). There was a substantial agreement using both the 3-tier and the 4-tier scoring for the viral load (Kendall concordance coefficients, 0.72 and 0.76, respectively; P < .001 for both). A better complete agreement was found using the 3-tier viral load score. In this first attempt to evaluate the interobserver reproducibility of the proposed Polyomavirus nephropathy classifying schema, we demonstrated moderate κ agreement in assessing the Polyomavirus nephropathy stage and a substantial agreement in scoring the viral load level. The proposed grading schema can be applied in routine allograft biopsy practice for grading the Polyomavirus nephropathy stage and the viral load level.


Asunto(s)
Rechazo de Injerto/patología , Enfermedades Renales/patología , Trasplante de Riñón/patología , Infecciones por Polyomavirus/patología , Poliomavirus/fisiología , Infecciones Tumorales por Virus/patología , Adolescente , Adulto , Anciano , Biopsia , Niño , Femenino , Rechazo de Injerto/clasificación , Rechazo de Injerto/tratamiento farmacológico , Rechazo de Injerto/virología , Humanos , Riñón/patología , Riñón/virología , Enfermedades Renales/clasificación , Enfermedades Renales/tratamiento farmacológico , Enfermedades Renales/virología , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Infecciones por Polyomavirus/clasificación , Infecciones por Polyomavirus/tratamiento farmacológico , Reproducibilidad de los Resultados , Estudios Retrospectivos , Trasplante Homólogo/patología , Infecciones Tumorales por Virus/clasificación , Infecciones Tumorales por Virus/tratamiento farmacológico , Carga Viral , Replicación Viral
7.
Indian J Pathol Microbiol ; 54(2): 335-8, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21623085

RESUMEN

BACKGROUND: Columnar cell lesions (CCLs) with or without atypia frequently coexist with invasive or in situ breast carcinomas. In this study, 39 mastectomy specimens containing CCLs coexisting with invasive carcinomas were retrospectively analyzed for cellular characteristics and structural pattern of CCL neighboring the tumor. MATERIALS AND METHODS: The expression of estrogen receptor (ER), progesterone receptor (PR), and p53 antibodies in CCL and coexisting invasive tumors, type of invasive tumor, histopathologic grade, and presence of atypia in CCL have been studied. RESULTS: Sixteen (41%) of all CCLs were with atypia, whereas 23 (59%) of them were without atypia. No correlations were found between the presence of CCLs with atypia and either the morphologic type of carcinoma or histopathologic grade of the tumors. Presence of atypia in the CCL was not correlated with the expression of p53 in the invasive tumors. CCLs without atypia dominated in Grade III tumors. The percentages of CCLs without atypia were also higher in both ER (-) and PR (-) tumors. CONCLUSIONS: CCL with atypia is generally considered to be a precursor of invasive carcinoma; however, in our study, CCLs without atypia more frequently coexisted with breast carcinoma.


Asunto(s)
Neoplasias de la Mama/patología , Carcinoma/patología , Neoplasias de la Mama/cirugía , Carcinoma/cirugía , Femenino , Expresión Génica , Humanos , Inmunohistoquímica , Mastectomía , Microscopía , Receptores de Estrógenos/análisis , Receptores de Progesterona/análisis , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Proteína p53 Supresora de Tumor/análisis
8.
Transplantation ; 90(6): 630-8, 2010 Sep 27.
Artículo en Inglés | MEDLINE | ID: mdl-20622753

RESUMEN

BACKGROUND: Infiltration of inflammatory cells into the renal allograft interstitium is the biologic hallmark of alloimmune responses that leads to tubulointerstitial injury and subsequent interstitial fibrosis and chronic allograft failure. The proliferation, stimulation, and infiltration of these inflammatory cells are governed by various proinflammatory and regulatory cytokines. We assessed whether the differences in the genes encoding cytokines (producing low, moderate, or high expression profiles) may affect the infiltration of inflammatory cells into the renal allograft and the histologic changes characteristics of chronic allograft failure. METHODS: A total of 218 kidney transplant recipients were genotyped for 15 single-nucleotide polymorphisms located in the gene promoter or exonic regions of 10 different cytokines or their receptors. Six- to 12-month posttransplant surveillance biopsies were scored using 11 individual histologic parameters and the combined grade of interstitial fibrosis and tubular atrophy (IF/TA). B-cell, T-cell, and macrophage infiltrates were quantified by immunostaining. RESULTS: The low-expressing interleukin (IL)-10 gene promoter genotypes were found significantly associated with high IF/TA grade (IL-10 -819 TT; P=0.035; odds ratio=3.27; 95% confidence interval 1.1-9.8). At individual histologic indices, recipients carrying low-expressing IL-10 genotypes showed 2.5-fold higher scores for interstitial fibrosis, inflammation, and tubular atrophy. High infiltration of T cells and macrophages but not B cells into the renal allograft interstitium was found strongly associated with the carriage of low-expressing IL-10 genotypes. CONCLUSIONS: The results suggest that renal transplant recipients genetically predisposed to low expression of the regulatory cytokine IL-10 are more susceptible to high grades of IF/TA scores, graft inflammation, and high influx of inflammatory cells into the graft interstitium.


Asunto(s)
Inflamación/patología , Interleucina-10/genética , Trasplante de Riñón/patología , Adulto , Biopsia , Citocinas/genética , Genotipo , Humanos , Inflamación/etiología , Inflamación/genética , Interferón gamma/genética , Proteína Antagonista del Receptor de Interleucina 1/genética , Interleucina-1/genética , Polimorfismo Genético , Polimorfismo de Nucleótido Simple , Estudios Retrospectivos , Trasplante Homólogo/patología , Factor de Necrosis Tumoral alfa/genética
9.
Clin J Am Soc Nephrol ; 5(3): 425-30, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20089495

RESUMEN

BACKGROUND AND OBJECTIVES: IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Accurately identifying patients who are at risk for progressive disease is challenging. The extent to which histopathologic features improves prognostication is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied a retrospective cohort with biopsy-proven IgAN in Calgary, Canada. Renal biopsies were reviewed by a nephropathologist with histopathologic data abstracted using a standardized form. The primary outcome was the composite of doubling of serum creatinine, ESRD, or death. Spline models defined significant levels of interstitial fibrosis, glomerulosclerosis, hypertension, proteinuria, and creatinine. The prognostic significances of clinical and histopathologic parameters were determined using Cox proportional hazards models. RESULTS: Data from 146 cases were available for analysis with a median follow-up of 5.8 years. Greater than 25% interstitial fibrosis, >40% glomerular sclerosis, and a systolic BP >150 mmHg were risk thresholds. In univariable analyses, baseline creatinine, proteinuria, systolic BP, glomerular sclerosis, interstitial fibrosis, and crescentic disease were predictors of the primary outcome. In multivariable models adjusted for clinical characteristics, interstitial fibrosis (hazard ratio [HR]2.7; 95% confidence interval [CI] 1.2 to 6.0), glomerular sclerosis (HR 2.6; 95% CI 1.2 to 4.5), and crescents (HR 2.4; 95% CI 1.2 to 5.1) remained independent predictors of the primary outcome and significantly improved model fit compared with clinical characteristics alone. CONCLUSIONS: Baseline histopathologic parameters are independent predictors of adverse outcomes in IgAN even after taking into consideration clinical characteristics. Relatively small degrees of interstitial fibrosis confer an increased risk for progressive IgAN.


Asunto(s)
Glomerulonefritis por IGA/diagnóstico , Fallo Renal Crónico/etiología , Glomérulos Renales/patología , Adulto , Alberta , Atrofia , Biomarcadores/sangre , Biopsia , Distribución de Chi-Cuadrado , Creatinina/sangre , Progresión de la Enfermedad , Femenino , Fibrosis , Glomerulonefritis por IGA/sangre , Glomerulonefritis por IGA/complicaciones , Glomerulonefritis por IGA/mortalidad , Glomerulonefritis por IGA/patología , Humanos , Hipertensión/complicaciones , Hipertensión/patología , Fallo Renal Crónico/sangre , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/patología , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Modelos de Riesgos Proporcionales , Proteinuria/etiología , Proteinuria/patología , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Esclerosis , Factores de Tiempo
10.
Cell Tissue Res ; 337(2): 223-34, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19471969

RESUMEN

Hypoxia is commonly found in human solid cancers and serves as a selective environment for the survival of aggressive cancer cells and as protection from anti-cancer therapies. In addition to a shift to anaerobic metabolism, the cellular response to hypoxia includes cessation of cell division and/or cell death. These mechanisms have still not been defined. Identification of the members of hypoxia-induced growth arrest pathways remain incomplete. We have undertaken an expression microarray analysis of the cellular response to hypoxia in diverse cell lines. An identified cohort of genes is reliably upregulated in various cells in response to hypoxia, as validated by reverse-transcriptase polymerase chain reaction (RT-PCR). One of the upregulated targets corresponds to an expressed sequence tag encoded by JMJD1A (a gene also known as JHDM2A), which has been identified as a histone demethylase that regulates the transcription of androgen receptor targets. We confirm, by RT-PCR, the upregulation of JMJD1A after hypoxia and desferroxamine treatment in multiple cell lines. We also show that JMJD1A is predominantly, but not exclusively, a nuclear protein. Immunofluorescent staining of HeLa cells shows a shift of cytoplasmic JMJD1A into the nucleus on hypoxia treatment. Immunohistochemical staining has revealed that JMJD1A is widely expressed in tissues, even in cells that are not known to express the androgen receptor, and is significantly increased in smooth muscle cells upon hypoxia treatment.


Asunto(s)
Regulación de la Expresión Génica , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Oxidorreductasas N-Desmetilantes/genética , Oxidorreductasas N-Desmetilantes/metabolismo , Hipoxia de la Célula/genética , Hipoxia de la Célula/fisiología , Células HeLa , Humanos , Inmunohistoquímica , Histona Demetilasas con Dominio de Jumonji , Análisis de Secuencia por Matrices de Oligonucleótidos , Regulación hacia Arriba/fisiología
11.
Leuk Res ; 33(6): 792-7, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19054557

RESUMEN

BACKGROUND: Rituximab, a chimeric antibody targeted to the human CD20 molecule, is a major component of the R-CHOP protocol used to treat patients with diffuse large B cell lymphoma (DLBCL). It is also a very expensive drug. Though the response rate of R-CHOP is higher than that of CHOP alone, patients may still experience a poor response. One possible mechanism that may mediate the poor response to R-CHOP is poor binding of the drug to the CD20 molecule, perhaps due to mutations or polymorphisms of the CD20 gene that affect its structure. To test this hypothesis and perhaps define a new predictor of R-CHOP response, our pilot study evaluated the CD20 gene sequence from patients exhibiting a poor outcome to R-CHOP. METHODS: Eleven patients with DLBCL who exhibited a recurrence of their disease and/or died within 24 months of R-CHOP treatment were categorized as showing poor progression-free survival (poor outcomes). Paraffin-embedded tissue specimens from the original tumors were evaluated for mutations or polymorphisms of the CD20 gene. Furthermore, sections from these patients and as well as from matched control patients who were categorized as good outcome patients (no progression of their disease within 36 months) were stained with anti-CD20 antibody and compared for CD20 protein expression. RESULTS: DNA sequence analyses revealed that no mutations were observed in DNA from the coding region of the CD20 gene in any of the initial tumors from 11 patients who showed poor outcomes with R-CHOP therapy. One case showed a synonymous single nucleotide polymorphism in exon 2 (C216T; rs2070770; Ile>>Ile). No significant differences in CD20 expression was observed between good and poor outcome patients with R-CHOP. CONCLUSIONS: Our results do not support association of CD20 mutations in specimens of the initial tumor or structural polymorphisms of the CD20 gene with patients who exhibited poor outcomes to R-CHOP.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antígenos CD20/genética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/genética , Mutación , Polimorfismo Genético , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales de Origen Murino , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Secuencia de Bases , Ciclofosfamida/administración & dosificación , Ciclofosfamida/uso terapéutico , Cartilla de ADN , Doxorrubicina/administración & dosificación , Doxorrubicina/uso terapéutico , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Prednisona/administración & dosificación , Prednisona/uso terapéutico , Rituximab , Vincristina/administración & dosificación , Vincristina/uso terapéutico
12.
Drugs ; 68 Suppl 1: 21-31, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18442298

RESUMEN

Chronic allograft nephropathy (CAN) is a common cause of late kidney transplant failure, characterized by progressive histological damage in the allograft. Although functional biomarkers such as creatinine are typically used to predict CAN, recent evidence suggests that composite, quantitative histological indices may be better predictors of long-term graft outcomes. Calcineurin inhibitors (CNIs) have been associated with major improvements in early rejection outcomes, but appear to cause both acute and chronic nephrotoxicity. The acute phase is associated with functional nephrotoxicity and is reversible with a reduction in CNI dosage, whereas the chronic phase is characterized by persistent histological lesions that are typically irreversible. Results from recent clinical trials suggest that converting from a CNI to sirolimus, withdrawing a CNI from a sirolimus-based regimen or using a CNI-free strategy may improve long-term outcomes by reducing CNI-related nephrotoxicity. However, in the de novo transplant setting, triple therapy with sirolimus, mycophenolate mofetil and corticosteroids is not recommended in combination with basiliximab induction. A treatment algorithm, based on the patient's histological score obtained on an allograft biopsy taken at approximately 6-12 months post-transplant, has been developed by our group and is described here.


Asunto(s)
Rechazo de Injerto/patología , Trasplante de Riñón/patología , Trasplante Homólogo/patología , Algoritmos , Inhibidores de la Calcineurina , Enfermedad Crónica , Humanos , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Enfermedades Renales/etiología , Enfermedades Renales/patología , Factores de Tiempo , Resultado del Tratamiento
13.
Transpl Int ; 20(7): 608-15, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17521383

RESUMEN

The most common cause of late kidney transplant failure is chronic allograft nephropathy (CAN). Much research has focused on identifying biomarkers (or correlates) that would predict subsequent CAN and allow timely intervention. Functional biomarkers such as serum creatinine and estimated glomerular filtration rate (eGFR) have been widely adopted, even though they have not been rigorously evaluated as surrogate markers. This study evaluated serum creatinine and eGFR for predicting the early histopathological changes seen in transplant protocol biopsies (TPB). We prospectively followed 289 kidney transplant patients in the Southern Alberta Transplant Program who had TPB at 6-12 months post-transplant. Tissue samples (n = 280) were independently examined by renal pathologists. The ability of serum creatinine or eGFR to predict the threshold level for abnormal histopathology was evaluated by calculating the area under the receiver operator characteristic curve. Serum creatinine and eGFR had poor predictive value (most confidence intervals included 0.5, indicating no predictive ability) for ten individual histological measurements (Banff 97 scores), and the Chronic Allograft Damage Index. We conclude that serum creatinine and eGFR have a limited clinical role in predicting the early histopathological changes that precede CAN and should not be used for this purpose.


Asunto(s)
Biomarcadores/sangre , Enfermedades Renales/patología , Enfermedades Renales/fisiopatología , Trasplante de Riñón/efectos adversos , Adulto , Enfermedad Crónica , Creatinina/sangre , Femenino , Tasa de Filtración Glomerular , Humanos , Riñón/patología , Riñón/fisiopatología , Enfermedades Renales/sangre , Enfermedades Renales/etiología , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Curva ROC , Trasplante Homólogo
14.
Dig Dis Sci ; 52(10): 2796-9, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17394064

RESUMEN

The aim of this study was to determine the risk of polyps <6 and between 6 and 10 mm in terms of progression to malignancy and to evaluate the influence of age, gender, and colonic localization on malignancy development. Thirteen hundred sixty-nine polyps <10 mm identified in 680 patients were retrospectively evaluated. Sixty-seven and two-tenths percent of polyps <10 mm were of a neoplastic nature. The incidence of neoplasia was higher in left-sided and small polyps than diminutive polyps. In patients older than 60 years, small polyps showed a higher rate of high-risk histology than diminutive polyps,while the same relationship did not exist in other age groups. In male patients over 60 years of age, the rate of high-risk histology was higher in small polyps than in diminutive polyps.


Asunto(s)
Transformación Celular Neoplásica/patología , Neoplasias del Colon/patología , Pólipos del Colon/patología , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Biopsia , Neoplasias del Colon/epidemiología , Pólipos del Colon/epidemiología , Colonoscopía , Progresión de la Enfermedad , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Factores Sexuales , Turquía/epidemiología
15.
Ren Fail ; 28(4): 315-21, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16771247

RESUMEN

OBJECTIVE: The aim of this study was to evaluate the importance of glomerular expression of von Willebrand factor (vWF) in human renal allografts. METHODS: We investigated graft biopsies from 72 renal transplant recipients, 40 with acute rejection (AR) and 32 with chronic allograft nephropathy (CAN). All biopsy specimens were immunostained with vWF and CD68 and graded using 3-tiered scales. The follow-up biopsies of patients with AR were reevaluated for development of glomerular sclerosis. RESULTS: A significant difference was found between type 1 and type 2 AR with regard to glomerular vWF expression (P < 0.01). None of the patients with type 1 AR showed mesangial vWF expression, but 36.4% of patients with type 2 AR showed segmental mesangial vWF expression. In follow-up biopsies, 18 of 40 patients developed significant glomerular sclerosis, and patients with mesangial vWF expression (grade 3 GvWF) showed glomerular sclerosis earlier than did others (P < 0.01). In addition, the outcome for grafts that showed grade 3 glomerular vWF was significantly worse than was the outcome noted for grafts that showed grade 1 or grade 2 glomerular vWF (P < 0.001). Half of the biopsy specimens in the CAN group showed global mesangial vWF expression. Glomerular macrophage infiltration was correlated with degree of glomerular vWF expression both in the AR and in the CAN groups (P < 0.05, P= 0.001, respectively). CONCLUSION: We hypothesized that the increasing amount of glomerular vWF may be used as a marker of acute vascular rejection and may help for the evaluation of renal allograft biopsies without sufficient arteries. In addition, it can also be a marker for development of early glomerular sclerosis and may help us determine which patients are in need of further treatment.


Asunto(s)
Rechazo de Injerto/metabolismo , Glomérulos Renales/metabolismo , Trasplante de Riñón , Factor de von Willebrand/metabolismo , Enfermedad Aguda , Adolescente , Adulto , Biopsia/métodos , Recuento de Células/métodos , Distribución de Chi-Cuadrado , Enfermedad Crónica , Progresión de la Enfermedad , Femenino , Humanos , Inmunohistoquímica , Trasplante de Riñón/fisiología , Macrófagos , Masculino , Persona de Mediana Edad , Estadísticas no Paramétricas , Trasplante Homólogo/fisiología
16.
Neuropathology ; 24(3): 243-7, 2004 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-15484703

RESUMEN

Chordoid meningioma is a rare variant of meningioma that bears a striking histological resemblance to chordoma and has greater likelihood of recurrence. Although most meningiomas occur in the intracranial, orbital and intravertebral cavities, rare meningiomas have been reported in extracranial organs; thus, it is important to be able to distinguish them from other neoplasms that have similar histology but different biological behavior and therapies. A case of chordoid meningioma in a 48-year-old woman who did not have Castleman's syndrome is described in the present report. The patient presented with a mass in her left frontoparietal region, and had been suffering from headaches for many years. Magnetic resonance imaging of the brain demonstrated an expansive lytic lesion in the squamous portion of the left temporal bone. The lesion extended in both directions. Histological examination of the surgical specimen revealed a tumor composed of cords and nests of eosinophilic vacuolated cells embedded in a myxoid matrix. A typical meningiomatous pattern was observed focally, and positive staining of the tumor cells for vimentin and epithelial membrane antigen confirmed the diagnosis of chordoid meningioma.


Asunto(s)
Neoplasias del Plexo Coroideo/patología , Meningioma/clasificación , Meningioma/patología , Femenino , Humanos , Neoplasias Meníngeas/patología , Persona de Mediana Edad
17.
Jpn J Thorac Cardiovasc Surg ; 52(12): 567-9, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15651402

RESUMEN

Mediastinal lymphangiomas are very rare tumors among the slow-growing mediastinal masses in the literature. We present the successful resection of a 52-year-old woman who was referred to our hospital. Past medical history consisted of surgical treatment for cervical mass and pathological diagnosis of lymphoma nine years earlier. She underwent postoperative radiotherapy. Preoperative chest roentgenogram and computed tomogram of the chest showed a cystic mass in the anterior mediastinum. The tumor was completely resected. The preoperative diagnosis was never questioned until the histopathological examination confirmed that the lesion was a cystic lymphangioma. Cystic lymphangiomas are benign tumors with the evidence of progression in tumor size and invasion into the vital structures. As our case shows, the tumor involvement with the vital structures causes difficulty in removal.


Asunto(s)
Linfangioma Quístico/cirugía , Neoplasias del Mediastino/cirugía , Femenino , Humanos , Linfangioma Quístico/diagnóstico por imagen , Linfangioma Quístico/patología , Neoplasias del Mediastino/diagnóstico por imagen , Neoplasias del Mediastino/patología , Persona de Mediana Edad , Radiografía Torácica , Procedimientos Quirúrgicos Torácicos/métodos , Tomografía Computarizada por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA